Santano Rivero, Desiree
Loading...
Email Address
person.page.identifierURI
Birth Date
Job Title
Last Name
Santano Rivero
First Name
Desiree
person.page.departamento
Ingeniería Eléctrica, Electrónica y de Comunicación
person.page.instituteName
ORCID
person.page.observainves
person.page.upna
Name
- Publications
- item.page.relationships.isAdvisorOfPublication
- item.page.relationships.isAdvisorTFEOfPublication
- item.page.relationships.isAuthorMDOfPublication
2 results
Search Results
Now showing 1 - 2 of 2
Publication Open Access Biophotonic platform for detection of hallmarks of Alzheimer's disease via combined microfluidics and nanofunctionalized fiber sensors(IEEE, 2023) Santano Rivero, Desiree; Lijiao, Zu; Jiwei, Xie; Peng, Liu; Zhang, Xuejun; Shi, Lei; Socorro Leránoz, Abián Bentor; Matías Maestro, Ignacio; Giannetti, Ambra; Baldini, Francesco; Santamaría Martínez, Enrique; Fernández Irigoyen, Joaquín; Li, Kaiwei; Bi, Wei; Van den Hove, Daniel L. A.; Del Villar, Ignacio; Guo, Tuan; Chiavaioli, Francesco; Ciencias de la Salud; Osasun Zientziak; Ingeniería Eléctrica, Electrónica y de Comunicación; Ingeniaritza Elektrikoa, Elektronikoa eta Telekomunikazio Ingeniaritza; Institute of Smart Cities - ISCThe emergence of Covid-19 pandemic has drawn large attention to vulnerable people affected by major diseases. According to the World Health Organization (WHO), more than 55 million people worldwide suffer from dementia. Alzheimer's disease (AD) is the predominant type of dementia, accounting for 60-70% of cases [1]. A long-standing challenge is to attain early diagnosis of AD hallmarks (tau protein, ¿P; amyloid beta, A¿) by detecting them in biological fluids, thus avoiding the labor of specialized hospital personnel and the high cost of imaging examinations. Different biological fluids are being used to detect AD biomarkers, such as cerebrospinal fluid (CSF), serum, blood-plasma [2]. Biomarker level in CSF has been shown to increase in the very early stages of the disease where its elevated value makes higher the risk of a quicker development of AD dementia. Traditional methods for biomarker detection are mostly based on ELISA or mass spectrometry, which possess well-known disadvantages in comparison with electrochemical or optical approaches [3,4].Publication Open Access Ultrahigh sensitive detection of tau protein as Alzheimer's biomarker via microfluidics and nanofunctionalized optical fiber sensors(Wiley, 2022) Chiavaioli, Francesco; Santano Rivero, Desiree; Del Villar, Ignacio; Socorro Leránoz, Abián Bentor; Zhang, Xuejun; Li, Kaiwei; Santamaría Martínez, Enrique; Fernández Irigoyen, Joaquín; Baldini, Francesco; Van den Hove, Daniel L. A.; Shi, Lei; Bi, Wei; Guo, Tuan; Giannetti, Ambra; Matías Maestro, Ignacio; Institute of Smart Cities - ISC; Ingeniería Eléctrica y Electrónica; Ingeniaritza Elektrikoa eta Elektronikoa; Universidad Pública de Navarra / Nafarroako Unibertsitate PublikoaAlzheimer’s disease (AD) is one of the most common neurodegenerative illnesses displaying the highest death rate in the elderly. However, the existing AD diagnostic system remains elusive due to lack of a technology that may ensure enough sensitivity and reproducibility, detection accuracy, and specificity. Herein, a straightforward approach is reported to realize lab-on-fiber (LoF) technology for AD biomarker detection based on a D-shaped single-mode fiber combined with nanometer-scale metal-oxide film. The proposed sensing system, which permits the generation of lossy-mode resonance (LMR), remarkably increases the evanescent field of light guided through the fiber, and hence the fiber-surrounding medium interaction. Moreover, such optical sensors are highly repeatable in results and can safely be embedded into a compact and stable microfluidic system. Herein, the specific detection of Tau protein (as one of the classical AD biomarkers that is highly correlated with AD progression) in a complex biofluid with a detection limit of 10 12 M and over a wide concentration range (10 3 –10 μg mL 1 ) is successfully demonstrated. The proposed LoF biosensor is an appealing solution for rapid, sub-microliter dose and highly sensitive detection of analytes at low concentrations, hereby having the potential toward early screening and personalized medicine in AD.